Systemic Lupus Erythematosus

3 articles published between March 9, 2026 and October 3, 2026.

Covered in Science and Body.

WHAT THE STUDY ACTUALLY SAYS

Tacrolimus matched mycophenolate for lupus nephritis over 96 weeks, with a safety twist

A randomised Asian trial in 130 patients found no efficacy gap between the two drug regimens for active lupus nephritis, but serious infections and all three deaths fell in the mycophenolate group.

3 min read

WHAT THE STUDY ACTUALLY SAYS

A CD40-ligand blocker improved lupus disease activity in a phase 3 trial

In PHOENYCS GO, dapirolizumab pegol lifted the share of lupus patients reaching a composite response at 48 weeks to 50% from 35% on placebo — a real but modest 14.6-point gain.

3 min read

WHAT THE STUDY ACTUALLY SAYS

Obinutuzumab beat placebo for active lupus outside the kidney in phase 3

In the ALLEGORY trial, 76.7% of patients with active SLE reached the SRI-4 response at 52 weeks on the B-cell–depleting antibody versus 53.5% on placebo, extending a drug already cleared for lupus nephritis.

4 min read

This page indexes this newspaper’s reporting on Systemic Lupus Erythematosus. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.